Skip to content
    Real-World Studies

    Real-World Efficacy and Safety of GemCis Plus Immunotherapy in Advanced Biliary Tract Cancer

    Kitahara et alCancers (Basel)

    A single-center retrospective study evaluated the real-world efficacy and safety of first-line gemcitabine and cisplatin (GemCis) combined with an immune checkpoint inhibitor (ICI)—durvalumab or pembrolizumab—in 26 patients with unresectable biliary tract cancer treated between and . Among the cohort, the median age was 73 years (range, 46–83 years), 57.7% were male, 84.6% had distant metastases, and 57.7% required biliary drainage. Primary tumor sites included gallbladder cancer (n = 11), intrahepatic cholangiocarcinoma (n = 8), perihilar cholangiocarcinoma (n = 6), and cancer of unknown primary origin (n = 1). Durvalumab was administered to 18 patients and pembrolizumab to eight patients.
    Over a median follow-up of 214 days (range, 30–1114 days), the overall response rate was 28.6%, the disease control rate was 90.5%, and 29.2% transitioned to ICI maintenance therapy. Median progression-free survival (PFS) was 8.2 months in the durvalumab group and 8.9 months in the pembrolizumab group, showing no statistically significant difference (p = 0.88). Immune-related adverse events (irAEs) occurred in 23.1% (6/26) of the overall population, with a significantly higher incidence in the pembrolizumab group compared to the durvalumab group (50.0% vs. 11.1%). Multivariable Cox proportional hazards analysis controlling for age, performance status, metastatic burden, and liver function identified age ≥ 75 years as the only independent prognostic factor for shorter PFS (HR 5.62; 95% CI, 1.35–23.4; p = 0.02), whereas biliary drainage and choice of ICI regimen did not significantly alter PFS outcomes. Authors noted limitations including the small cohort size, non-statistically powered comparative analyses, and the exploratory nature of safety findings between specific ICIs.

    Key Takeaways

    • In a real-world cohort receiving gemcitabine and cisplatin plus immune checkpoint inhibitor therapy for unresectable biliary tract cancer, age ≥ 75 years was the only independent predictor of shorter progression-free survival (HR 5.62; 95% CI, 1.35–23.4; p = 0.02), whereas biliary drainage and choice of agent were not significant prognostic factors.
    • Median progression-free survival did not significantly differ between durvalumab and pembrolizumab when combined with gemcitabine and cisplatin (8.2 vs. 8.9 months, p = 0.88), though immune-related adverse events were significantly more frequent with pembrolizumab (50.0% vs. 11.1%).
    • Across all patients receiving gemcitabine and cisplatin plus immune checkpoint inhibitor therapy, the overall response rate was 28.6%, the disease control rate was 90.5%, and 29.2% of patients successfully transitioned to maintenance immunotherapy.